Roivant Sciences to Present PHOCUS Study Results at ERS Congress 2026

Roivant Sciences, in collaboration with Pulmovant Therapeutics, will present top-line results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the European Respiratory Society (ERS) International Congress 2026. The presentation, scheduled for Tuesday, September 8, 2026, at 12:15 CEST (6:15 a.m. ET), will be delivered by Dr. Marc Humbert, a Professor of Respiratory Medicine at Université Paris-Saclay and the Director of the French National Reference Center for Pulmonary Hypertension.

Roivant will also host an investor call at 8:00 a.m. ET on the same day. To participate in the call, investors must register online using the provided link. Details of the presentation and webcast will be available on the "Events & Presentations" page of the Roivant website, which can be accessed via www.investor.roivant.com/news-events/events. The archived webcast will be available on the company’s website after the conference.

Mosliciguat, an inhaled sGC activator, is part of Roivant’s pipeline, which also includes LISRAYA™ (brepocitinib) and IMVT-1402. LISRAYA™ is a potent small molecule inhibitor of JAK1 and TYK2, approved for dermatomyositis in adult patients and in late-stage development for non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris. IMVT-1402 is a fully human monoclonal antibody targeting FcRn in development for several IgG-mediated autoimmune indications.

Roivant is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of medicines that make a difference in patients' lives. The company advances its pipeline through the creation of nimble subsidiaries or “Vants” dedicated to developing and commercializing its medicines and technologies.